Pharmaceutical Industry Business Confidence Report H2 2016
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The existing economic environment is stable for the pharmaceutical industry, and customer confidence levels will remain constant in H2 2016 (July 2016–December 2016). Companies are slightly optimistic about economic conditions in North America and the Asia-Pacific due to positive momentum in the US, firm domestic demand, and strong government expenditure in India. The pharmaceutical industry is expected to record higher expenditure towards new product development and mergers and acquisitions in H2 2016 as compared to H1 2016. Moreover, executives with business operations in the Asia-Pacific and Europe expect increase in raw material prices in H2 2016 as compared to H1 2016.
Scope
Economic environment is more favorable in Eastern Europe and Australasia in H2 2016 as compared to H1 2016
The majority of respondents communicated optimism about company and industry growth prospects for the next six months
Globally, supplier prices of ingredients are anticipated to increase by 2.5% over the next six months
Survey results indicate highest increase in spending on new product development in H2 2016 as compared to H1 2016
Respondents with business operations in Asia-Pacific are more concerned about the performance of developing economies in H2 2016 as compared to H1 2016
Organizations intend to focus on new product development and improving operational efficiency during the next six months
Reasons to Buy
Helps organizations to make effective business strategy decisions by knowing the prevailing business conditions and sentiment within the pharmaceutical industry
Organizations will be supported in business expansion decisions by providing information about projected change in sales performance and supplier prices
Helps to improve operational efficiency of the organization by knowing about key priorities and the main concerns of pharmaceutical industry executives
Helps to alter investment allocation by understanding key focus areas highlighted by survey respondents during H2 2016
Sanofi S.A.
Novartis International AG
Mylan N.V.
PeptiDream
Genentech
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.